Format

Send to

Choose Destination
Drug Discov Today. 2012 Jun;17(11-12):583-90. doi: 10.1016/j.drudis.2012.01.007. Epub 2012 Jan 24.

Immunocytokines: a novel class of potent armed antibodies.

Author information

1
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Zürich, Switzerland.

Abstract

Several cytokines have been investigated in clinical trials, based on their potent therapeutic activity observed in animal models of cancer and other diseases. However, substantial toxicities are often reported at low doses, thus preventing escalation to therapeutically active regimens. The use of recombinant antibodies or antibody fragments as delivery vehicles promises to enhance greatly the therapeutic index of pro-inflammatory and anti-inflammatory cytokines. This review surveys preclinical and clinical data published in the field of antibody-cytokine fusions (immunocytokines). Molecular determinants (such as molecular format, valence, target antigen), which crucially contribute to immunocytokine performance in vivo, are discussed in the article, as well as recent trends for the combined use of this novel class of biopharmaceuticals with other therapeutic agents.

PMID:
22289353
DOI:
10.1016/j.drudis.2012.01.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center